Novel Strategies in Managing Patients With High-Risk Chronic Lymphocytic Leukemia
Key opinion leaders provide their perspective on the optimal management of high-risk chronic lymphocytic leukemia with novel therapeutic agents.
Read More
Chronic Lymphocytic Leukemia: Novel Therapies in the Pipeline
Exciting novel-based treatment strategies being investigated in chronic lymphocytic leukemia.
Novel Combination Regimens for Chronic Lymphocytic Leukemia
Implications for treating chronic lymphocytic leukemia with small molecule combination regimens in the frontline setting.
PI3K Inhibitors for Chronic Lymphocytic Leukemia
The rationale for investigating and using PI3K inhibitors to treat chronic lymphocytic leukemia.
Individualizing Therapy for Patients With Newly Diagnosed CLL
Susan O’Brien, MD, and Anthony Mato, MD, MSCE, describe their preferences for treating newly diagnosed chronic lymphocytic leukemia based on disease presentation and patient variables.
Frontline Anti-CD20 Therapy in CLL
The rationale for integrating CD20 monoclonal antibody therapy into the frontline setting of chronic lymphocytic leukemia.
Frontline Targeted Therapy for Newly Diagnosed High-Risk CLL
Frontline therapies available to treat newly diagnosed high-risk chronic lymphocytic leukemia, and the rationale for selecting a targeted therapy versus chemoimmunotherapy as initial treatment.
Impressions Regarding an Atypical Case of High-Risk CLL
Reactions to an atypical diagnosis of high-risk chronic lymphocytic leukemia in a 61-year-old man.
Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC
Dr Sands on the Evolving Role of ADCs in SCLC Management
Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC
MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer